By Elric Langton | 23 February 2024
I have a financial interest in Aptamer Group.
Aptamer Group develops novel Optimerยฎ binders that enable innovation in the life sciences industry. The company has announced the second phase of its partnership with Neuro-Bio, a biotechnology company focused on developing therapeutics for neurodegenerative diseases. The partnership aims to develop Optimer binders for a lateral flow test for the early diagnosis of Alzheimer's disease.
The partnership's second phase involves developing an additional Optimer binder against a novel target implicated in Alzheimer's disease. The goal is to create reagents for a lateral flow test for early disease detection. This development is significant because it has the potential to revolutionise the way Alzheimer's disease is diagnosed. Current diagnostic methods are invasive and expensive, making them inaccessible to many patients. A lateral flow test, on the other hand, is a simple and cost-effective diagnostic tool that can detect the disease early, allowing for more effective treatment and management.